APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03502330

Recruitment Status : Recruiting

First Posted : April 18, 2018

Last Update Posted : December 22, 2020

See Contacts and Locations

Sponsor:

Collaborators:

Bristol-Myers Squibb

Apexigen, Inc.

Information provided by (Responsible Party):

Yale University

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	May 2022
Estimated Study Completion Date :	October 2024

To Top